On this page
Leber congenital amaurosis (GUCY2D)
LCA due to GUCY2D variants is a genetic condition affecting the retina, the light-sensing tissue at the back of the eye. It typically causes significant vision loss very early in life, often noticed in newborns or young infants.
Available at Jeen Health
Clinical tests that include this
Overview
Leber congenital amaurosis (LCA) is a group of inherited eye conditions that cause severe vision loss from a very young age. It is the most common genetic cause of blindness in infants and young children [PMID:20301323]. Individuals with LCA often have profoundly impaired vision at birth or within the first few months of life. While many different genes can cause LCA, pathogenic changes in the GUCY2D gene are one recognised cause.
LCA affects the retina, which is the specialised light-sensitive tissue at the back of the eye. The retina converts light into electrical signals that are sent to the brain, allowing us to see. In LCA, the retinal cells do not function correctly, leading to poor vision.
Symptoms & clinical features
The primary symptom of LCA is severe vision impairment or blindness present from birth or developing within the first few months of life. Parents may notice that an infant does not respond to visual stimuli or has unusual eye movements. Common signs include nystagmus (involuntary, rapid eye movements), poor pupillary light reflexes, and oculodigital sign (children pressing, rubbing, or poking their eyes). Eye rubbing can sometimes lead to deep-set eyes or keratoconus (a thinning of the cornea).
Other symptoms can include photophobia (sensitivity to light) and hyperopia (long-sightedness). Although the vision loss is typically severe, the condition is not usually progressive in the sense that vision rarely worsens significantly over time beyond its initial presentation [PMID:20301323]. However, the degree of vision impairment can vary between individuals, even within the same family.
Video: Genetics 101
Affected organs
Leber congenital amaurosis primarily affects the eyes, specifically the retina. The retina contains specialised cells called photoreceptors (rods and cones) that detect light. In individuals with LCA, these cells, particularly the cone photoreceptors, do not develop or function correctly, leading to impaired vision. While the condition primarily affects vision, it does not typically impact other organ systems in the body.
Risks & severity
LCA is characterised by severe vision loss from birth or early infancy. The severity of vision impairment can range from very poor vision to complete blindness, though some individuals may retain a degree of light perception or minimal useful vision. The condition is generally considered stable after its initial presentation, meaning vision typically does not progressively worsen significantly over time [PMID:20301323]. However, complications like cataracts or keratoconus can sometimes develop and may affect vision further.
The exact prevalence of LCA specifically caused by GUCY2D variants is not well established, but GUCY2D is considered one of the more common genetic causes of LCA, accounting for a notable proportion of cases [PMID:28795587].
Genetic causes
Leber congenital amaurosis can be caused by pathogenic changes in several different genes. In some cases, LCA is caused by variants in the GUCY2D gene. GUCY2D provides instructions for making an enzyme called guanylate cyclase 2D. This enzyme plays a crucial role in the phototransduction cascade, which is the process by which light is converted into electrical signals in the retina.
Specifically, guanylate cyclase 2D helps to regulate levels of a molecule called cGMP in the photoreceptor cells. This regulation is essential for the cells to respond to light and then recover to be ready for the next light signal. When there are pathogenic variants in GUCY2D, the enzyme cannot function correctly, disrupting the phototransduction process and leading to the severe vision impairment seen in LCA.
- GUCY2D guanylate cyclase 2D, retinalThe GUCY2D gene provides instructions for a protein critical in the visual cycle, playing a key role in the retina's ability to detect light and colours.
Inheritance pattern
Leber congenital amaurosis caused by GUCY2D variants is inherited in an autosomal recessive pattern. This means that an individual must inherit two pathogenic variants, one from each parent, to develop the condition. People who have only one pathogenic variant in GUCY2D are called carriers; they typically do not show symptoms of LCA themselves but can pass the variant on to their children.
If both parents are carriers of a GUCY2D pathogenic variant, for each pregnancy, there is a 25% chance their child will inherit two copies of the variant and develop LCA. There is a 50% chance the child will be a carrier like their parents, and a 25% chance the child will inherit two unaffected copies of the gene and not be affected or a carrier.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
The diagnosis of Leber congenital amaurosis is initially based on the characteristic clinical signs and symptoms, particularly severe vision impairment from infancy. An ophthalmologist (eye specialist) will perform a thorough eye examination. Electrophysiological tests, such as electroretinography (ERG), are often crucial. An ERG measures the electrical responses of the retina to flashes of light; in LCA, the ERG responses are typically severely reduced or absent.
Confirmation of LCA, and identifying the specific genetic cause, usually involves genetic testing. In the UK, genetic testing for inherited retinal diseases like LCA is available through the NHS Genomic Medicine Service (GMS) pathways. A clinical geneticist or an ophthalmologist specialising in inherited eye conditions can refer individuals for testing. The relevant NHS National Genomic Test Directory R-code for inherited retinal disorders, including LCA, is R85.
Management & lifestyle
While there is currently no cure for Leber congenital amaurosis, management focuses on optimising residual vision, providing support, and addressing associated complications. Early diagnosis is important to access appropriate support and educational resources. Children may benefit from visual aids, rehabilitation services, and educational programmes designed for those with severe vision impairment.
Regular follow-up with an ophthalmologist is recommended to monitor eye health and manage potential complications such as cataracts, glaucoma, or keratoconus. Genetic counselling is an important part of the care pathway for individuals and families affected by LCA, offering information about the condition, inheritance patterns, and reproductive options. Research into gene therapies for various forms of LCA, including GUCY2D-related LCA, is ongoing and may offer future treatment possibilities [PMID:33678082].
UK care pathway
In the UK, individuals with suspected Leber congenital amaurosis will typically be referred to a specialist ophthalmology service. Following a clinical assessment, if an inherited retinal condition is suspected, referral to a clinical genetics service or an ophthalmologist with expertise in inherited eye diseases is usually the next step. Genetic testing, using the NHS National Genomic Test Directory R-code R85 for inherited retinal disorders, can help confirm the diagnosis and identify the specific genetic cause. Genetic counsellors play a vital role in providing information and support to families undergoing genetic testing and navigating the implications of a diagnosis.
Frequently asked questions
What is the typical age of onset for GUCY2D-related LCA?
Leber congenital amaurosis caused by GUCY2D variants typically presents with severe vision impairment from birth or within the first few months of life. It is often detected when infants do not respond to visual cues or exhibit unusual eye movements.
Is GUCY2D-related LCA progressive, meaning does vision get worse over time?
Generally, the severe vision loss associated with GUCY2D-related LCA is present from early life and is not considered progressively worsening over time. Vision is typically stable after its initial presentation, although complications can sometimes arise.
Can carriers of GUCY2D variants develop symptoms?
No, individuals who are carriers of a single pathogenic GUCY2D variant typically do not develop symptoms of Leber congenital amaurosis. They carry one copy of the variant but have enough functional protein from their other GUCY2D copy to maintain normal vision.
Are there any treatments for GUCY2D-related LCA?
Currently, there is no cure for GUCY2D-related LCA. Management focuses on supporting individuals with vision impairment through visual aids, rehabilitation, and educational resources. Research into gene therapy approaches for various forms of LCA, including GUCY2D, is an active area of study.
How is genetic testing for LCA accessed in the UK?
In the UK, genetic testing for inherited retinal disorders like LCA is available through the NHS Genomic Medicine Service (GMS). A referral from a specialist, such as an ophthalmologist or clinical geneticist, is usually needed to access this testing, often under the R85 R-code.